1GDA Stock Overview
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zevra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.05 |
| 52 Week High | US$9.20 |
| 52 Week Low | US$3.80 |
| Beta | 2 |
| 1 Month Change | -6.40% |
| 3 Month Change | 10.27% |
| 1 Year Change | 83.79% |
| 3 Year Change | 2.55% |
| 5 Year Change | 1.03% |
| Change since IPO | -97.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1GDA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -2.2% | -2.0% |
| 1Y | 83.8% | -15.8% | 6.8% |
Return vs Industry: 1GDA exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 1GDA exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 1GDA volatility | |
|---|---|
| 1GDA Average Weekly Movement | 7.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1GDA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1GDA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 67 | Neil McFarlane | zevra.com |
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.
Zevra Therapeutics, Inc. Fundamentals Summary
| 1GDA fundamental statistics | |
|---|---|
| Market cap | €435.44m |
| Earnings (TTM) | -€86.16m |
| Revenue (TTM) | €23.53m |
18.7x
P/S Ratio-5.1x
P/E RatioIs 1GDA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1GDA income statement (TTM) | |
|---|---|
| Revenue | US$24.49m |
| Cost of Revenue | US$8.05m |
| Gross Profit | US$16.44m |
| Other Expenses | US$106.10m |
| Earnings | -US$89.66m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | 67.13% |
| Net Profit Margin | -366.14% |
| Debt/Equity Ratio | 84.4% |
How did 1GDA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 13:59 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zevra Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dewey Steadman | Canaccord Genuity |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Louise Chen | Cantor Fitzgerald & Co. |